1、教育经历
(1) 2003/09-2008/06,中国药科大学, 药物分析,博士
(2) 1999/09-2003/06,中国药科大学, 药学, 学士
2、工作经历
(1) 2021/07-至今 中国药科大学,药学院,教授
(2) 2015/08-2016/08,美国麻省州立大学阿默斯特分校,访问学者
(3) 2011/07-2021/06, 中国药科大学, 药学院,副教授
(4) 2008/06-2011/06, 中国药科大学, 药学院,讲师
3、学术荣誉
2018/07 江苏省双创人才科技副总
4、学术兼职
2021/01 中国医药教育协会制药专业技术委员会副主任委员
(1) 化学药物质量控制
(2) 多肽药物质量控制
(3) 药物筛选检测技术
1、科研项目
(1)科技部, 国家重点研发计划政府间重点专项项目,SQ2021YFE011110,工程化干细胞疗法治疗哮喘的机制研究,2022-01 至 2024-12,100万元,在研,主持
(2)国家自然科学基金委员会,国际(地区)合作与交流项目(重点项目),82020108029,调节病理屏障正常化逆转肝纤维化的机制研究,2021-01-01 至 2025-12-31,248万元,在研,主持
(3)国家自然科学基金委员会,国际(地区)合作与交流项目(交流项目),81811540416,肝纤维化的基因治疗,2018-07-01 至 2020-06-30,10万元,已结题,主持
(4)国家自然科学基金委员会,面上项目,81773667,三位一体治疗Leber遗传性视神经病变的基因递送系统的理性设计与功效研究,2018-01-01 至 2021-12-31,67万元,已结题,主持
(5)江苏省科技厅,江苏省自然科学基金杰出青年基金项目,BK20160031,智能型纳米载体核定向传递Cas9蛋白复合体精准敲除肝癌H-Ras突变的研究,2016-07 至 2019-06,100万元,已结题,主持
(6)国家自然科学基金面上项目,81573369,肝星状细胞靶向的时空稳定可控的类脂质囊泡用于复合siRNA治疗肝纤维化的研究,2016-01至2019-12,60万元,已结题,主持
(7)江苏省自然科学基金青年基金项目,BK20140659,pH响应性一体双能载体用于肿瘤细胞靶向治疗,2014-07至2017-06,20万元,已结题,主持
(8)江苏省“六大人才高峰”高层次人才项目,YY011,纳米基因工程用于肺癌靶向治疗,2014-08至2017-07,10万元,已结题,主持
(9)江苏省特聘教授计划项目,02410558,生物相容性多功能载体研究,2012-01至2014-12,200万元,已结题,主持
2、学术获奖
(1)2018-08,中国颗粒学会青年颗粒学奖,排名第一
3、专利转化
(1)肺纤维化高端制剂转让及开发,专利技术转让,燃点(南京)生物医药科技有限公司,2000万元,2021-05
1)Ying He, Haotian Ding, Xingya Xia, Wenyi Qi, Huaisong Wang, Wenyuan Liu*, Feng Zheng*. GFP-fused yeast cells as whole-cell biosensors for genotoxicity evaluation of nitrosamines. Applied Microbiology and Biotechnology. 2021,105: 5607–5616 (IF 4.8)
2)Mingxian Li, Congcong Gu, Lan Luo, Jie Zhou, Jing Liu*, Feng Zheng*. Determination of trace methanesulfonates in drug matrix using derivatization and headspace single drop microextraction followed by high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography A. 2019, 1951: 131-137 (IF 3.86)
3)Shunli Ji, Hongbin Gao, Xingya Xia, Feng Zheng*. A new HPLC-UV derivatization approach for the determination of potential genotoxic benzyl halides in drug substances. RSC Advances. 2019, 9: 25797-25804 (IF 3.05)
4)Lan Luo, Congcong Gu, Mingxian Li, Xiangyuan Zheng, Feng Zheng*. Determination of residual 4-nitrobenzaldehyde in chloramphenicol and its pharmaceutical formulation by HPLC with UV/Vis detection after derivatization with 3-nitrophenylhydrazine. Journal of Pharmaceutical and Biomedical Analysis. 2018, 156: 307-312 (IF 2.83)
5)Jie Zhou, Mingxian Li, Lan Luo, Hongbin Gao, Feng Zheng*. Photodegradation of Moxifloxacin Hydrochloride Solutions under Visible Light Irradiation: Identification of Products and the Effect of pH on their Formation. AAPS PharmSciTech, 2018, 19: 1182-1190 (IF 2.60)
6)Xiangyuan Zheng, Lan Luo, Jie Zhou, Xiaoling Ruan, Wenyuan Liu*, Feng Zheng*. Development and validation of a general derivatization HPLC method for the trace analysis of acyl chlorides in lipophilic drug substances. Journal of Pharmaceutical and Biomedical Analysis, 2017, 140: 327-333 (IF 3.26)
7)Jie Zhou, Jie Xu, Xiangyuan Zheng, Wenyuan Liu*, Feng Zheng*. Determination of methyl methanesulfonate and ethyl methanesulfonate in methanesulfonic acid by derivatization followed by high-performance liquid chromatography with ultraviolet detection. Journal of separation science, 2017, 40: 3414–3421. (IF 2.42)
8)Han Lingfei, Hou Desheng; Ma Congyu Fu Na, Liu Jing, Feng Feng, Liu Wenyuan*, Zheng, Feng*. Simultaneous determination of eight short-chain aliphatic amines in drug substances by HPLC with diode array detection after derivatization with halonitrobenzenes. Journal of separation science. 2017, 40:3074-3085. (IF 2.42)
9)Desheng Hou, Jingjing Fan, Lingfei Han, Xiaoling Ruan, Feng Feng, Wenyuan Liu*, Feng Zheng*. Determination of small halogenated carboxylic acid residues in drug substances by high performance liquid chromatography-diode array detection following derivatization with nitro-substituted phenylhydrazines. Journal of Chromatography A, 2016,1438: 46-56. (IF 3.92)